IHS Chemical Week

Markets :: Specialty Chemicals :: Catalysts

Albemarle earnings fall on discontinued operations, but beat estimates

3:31 PM MDT | July 30, 2014 | Vincent Valk

Albemarle today reported second-quarter down 73% year-on-year (YOY), to $22.5 million, on sales up 5%, to $604.7 million. Net income fell due to an accounting loss on discontinued operations, namely the antioxidants, ibuprofen and propofol businesses Albemarle sold to SI Group during the quarter. Excluding this loss, and other, smaller, charges, adjusted earnings grew 10% YOY, to $86.8 million, or $1.10/share, ahead of analysts’ consensus estimate of $1.07/share, as reported by Thomson Reuters (New York). "Improved trends drove stronger than expected...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa